HeartBeam Wins FDA Breakthrough Status for At-Home Heart Attack Detection
Event summary
- HeartBeam's 3D ECG system received FDA Breakthrough Device Designation for assessing potential heart attacks at home.
- Designation granted within 30 days of request, ahead of FDA's 60-day review period.
- Company estimates $15B market opportunity for heart attack detection within broader $40B cardiac platform.
- Breakthrough status enables prioritized FDA review and potential expedited Medicare coverage.
- HeartBeam plans multicenter pivotal study to support future FDA submission for heart attack assessment.
The big picture
HeartBeam's Breakthrough Device Designation addresses a critical gap in heart attack care by enabling at-home assessment, potentially reducing delays in treatment. The designation positions HeartBeam for prioritized FDA review and expedited Medicare coverage, accelerating its path to market in a $15B segment of the broader $40B cardiac platform. The company's 3D ECG technology, already cleared for arrhythmia assessment, now targets a larger opportunity in acute cardiac event detection.
What we're watching
- Regulatory Alignment
- How quickly HeartBeam can achieve FDA alignment on its pivotal study design and secure expedited Medicare coverage through the RAPID pathway.
- Clinical Validation
- Whether the upcoming ALIGN-ACS data presentation and HEADSTART-ACS study will provide sufficient clinical evidence to support FDA clearance.
- Market Penetration
- The pace at which HeartBeam can commercialize its technology given the $15B heart attack detection market opportunity.
Related topics